In our multicenter study, we identified that a shorter disease duration, a positive anti‐MuSK antibody, and the AA genotype in FCGR2A rs1801274 were significant predictors for achieving a clinical response within 6 months in MG patients treated with rituximab of 600 mg. Here, FCGR2A is linked to myasthenia gravis.